|
|
|
|
GSK: Rare Diseases Now Big Business
Theres nothing quite like Big Pharma trying to reinvent itself.Although it would be wildly premature to suggest GlaxoSmithKlines move into rare disease research, hot on the heels of Pfizer, is the death knell for mass-market blockbuster drugs, it sure is...
|
|
|
GSK forms new specialized R&D unit
GSK has established a new standalone unit specialising in the development and commercialisation of medicines for rare diseases Marc Dunoyer, president of Asia Pacific and chairman of Japan at GSK, is expected to lead the new operation, working closely with...
|
|
|
GSK Launches Special Disease Unit
GlaxoSmithKline (GSK) has announced the formation of a new specialised unit to research and develop treatments for rare diseases.The new unit will leverage off strategic collaborations formed in 2009 with two specialist companies, Prosensa and JCR...
|
|
|
PREVIEW-Genzyme competition may get clearer at conference
* What: Lysosomal Disease Network World Congress * When: Feb.10-12 * Genzyme, Shire, Protalix to present Gaucher data BOSTON, Feb 8 (Reuters) - Genzyme Corp <GENZ.O>, Shire Plc <SHP.L> and Protalix Biotherapeutics Inc <PLX.A>...
|
|
|
Genzyme competition may get clearer at conference
* Genzyme, Shire, Protalix to present Gaucher data BOSTON, Feb 8 (Reuters) - Genzyme Corp, Shire Plc and Protalix Biotherapeutics Inc will each be presenting data this week that could give hints as to how the competitive landscape for Gaucher...
|
|
|
PREVIEW-Genzyme competition may get clearer at conference
By Toni Clarke BOSTON, Feb 8 (Reuters) - Genzyme Corp, Shire Plc and Protalix Biotherapeutics Inc will each be presenting data this week that could give hints as to how the competitive landscape for Gaucher disease treatments could look a year or two from...
|
|
|
PREVIEW-Genzyme competition may get clearer at conference
BOSTON, Feb 8 (Reuters) - Genzyme Corp, Shire Plc and Protalix Biotherapeutics Inc will each be presenting data this week that could give hints as to how the competitive landscape for Gaucher disease treatments could look a year or two from now.
|
|
|
GlaxoSmithKline, Poniard, Protalix Provide Biotech's Latest Mishaps
The Burrill Report submits: GlaxoSmithKline ( GSK ) will cut up to 4,000 jobs as the drug giant seeks to cut costs in the face of the loss of revenue from generic competition, The Sunday Times reported.The latest job cuts come as the company puts greater...
|
|
|
GSK: Rare Diseases Now Big Business
Theres nothing quite like Big Pharma trying to reinvent itself.Although it would be wildly premature to suggest GlaxoSmithKline s move into rare disease research, hot on the heels of Pfizer , is the death knell for mass-market blockbuster drugs, it sure is...
|
|
|
'Israel Pharmaceuticals & Healthcare Report Q1 2010' now available at Fast Market Research
Israel continues to slide down BMI's Business Environment Ratings table, as the Q110 update sees it now ranking 12th out of the 17 Middle East and African (MEA) markets surveyed.Globally, Israel is judged to be the tenth least-attractive pharmaceutical...
|
|
|
GSK launches new specialist unit to research and develop medicines for rare diseases
GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases London, UK | February 4, 2010 | GSK today announces the formation of a new standalone unit specialising in the...
|
|
|
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
GSK announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.Over 5,500 rare diseases have been identified(1) of which less than 10% are currently being treated(2), presenting a...
|
|
|
Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lys
Data sponsored by the Canadian Fabry Disease Initiative (CFDI) to be presented by Dr.Michael West, Dalhousie University CAMBRIDGE, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Shire plc , the global specialty biopharmaceutical company, today announced...
|
|
|
Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network
CARMIEL, Israel, Feb.4 /PRNewswire-FirstCall/ -- Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual...
|
|
|
Protalix Announces Presentation of Phase III Taliglucerase Alfa Data at WORLD Lysosomal Disease Network
CARMIEL, Israel, Feb.4 /PRNewswire-FirstCall/ Protalix Biotherapeutics, Inc. (NYSE- Amex: PLX) today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting...
|
|
|
Protalix Announces Presentation Of Phase III Taliglucerase Alfa Data At WORLD Lysosomal Disease Network
Protalix Biotherapeutics, Inc.(NYSE- Amex: PLX) announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium...
|
|
|
FDA wants more info on Protalix Gaucher drug
Protalix Biotherapeutics has suffered a setback in its bid to compete with Genzymes Cerezyme after regulators in the USA asked for more information on the Israeli companys experimental Gaucher disease drug taliglucerase alfa.Protalix filed a New Drug...
|
|
|
GSK may venture into rare disease treatments
LONDON (Feb.5) GlaxoSmithKline has identified more than 5,500 rare diseases it could potentially target as part of a new drug-development initiative, the British drug maker announced Thursday. GSK said it would start a new standalone business unit...
|
|
|
US FDA seeks more data from Protalix's taliglucerase alfa NDA to treat Gaucher disease
_ US FDA seeks more data from Protalix's taliglucerase alfa NDA to treat Gaucher disease.
|
|
|
GSK launches new research unit
GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.Over 5,500 rare diseases have been identified1 of which less than 10% are currently being treated2, presenting a...
|
|
|
GSK launches new specialist unit to research and develop medicines for rare diseases
Let the jobs come to you!GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases! Over 5,500 rare diseases have been identified1 of which less than 10% are currently...
|
|
|
GSK launches specialist unit for rare diseases
GSK has formed a new standalone unit specializing in the development and commercialization of medicines for rare diseases.Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a significant unmet medical...
|
|
|
Neglected no more
There is a renewed focus on rare diseases and neglected tropical diseases, thanks to incentives offered under the US Orphan Drug Legislation and its extension, the Priority Review Voucher scheme.What are the new business models emerging from this strategy...
|
|
|
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
GSK recently announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a...
|
|
|
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
GSK recently announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a...
|
